Research Progresses on Pharmaceutical Co-crystals of the Cardiovascular and Cerebrovascular Diseases Treatment Drugs
10.3870/j.issn.1004-0781.2019.02.010
- VernacularTitle:心脑血管疾病治疗药物共晶研究进展
- Author:
Penghui YUAN
1
;
Dezhi YANG
;
Kun HU
;
Guanhua DU
;
Li ZHANG
;
Yang LYU
Author Information
1. 北京协和医学院中国医学科学院药物研究所晶型药物研究北京市重点实验室
- Keywords:
Treatment drugs,cardiovascular and cerebrovascular diseases;
Co-crystal;
Polymorphism
- From:
Herald of Medicine
2019;38(2):187-192
- CountryChina
- Language:Chinese
-
Abstract:
The pharmaceutical co-crystal has attracted a lot of attention in recent years as a new direction in the research of polymorphism drugs. The research on pharmaceutical co-crystal has scientific significance for improving the solubility, bioavailability and physical or chemical stability of drugs. In this paper, from the perspective of drugs for the treatment of cardiovascular diseases(including five major types: heart failure, hypertension, coronary heart disease and arrhythmia, stroke) , the latest research results of pharmaceutical co-crystal reported in recent years are reviewed, hope to provide reference for the follow-up research and promote the development of pharmaceutical co-crystal in China.